Sun Pharmaceutical Industries growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+11.2%+8.4%+10.5%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+16.1%+17.3%+11.8%
+16.5%+21.3%+14.8%
+5.0%+14.1%+12.9%
+4.8%+14.3%+13.0%
+18.1%+7.8%+5.8%
+15.7%+8.0%+13.1%
−11.7%+16.0%+144.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUNPHARMA₹1,761.00

Sun Pharmaceutical Industries Ltd.

· Pharma & Health
₹ CrorePeersCIPLADRREDDYLUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹4.23L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+10.5+8.4+11.2—
EBITDA Growth—+11.8+17.3+16.1—
EBIT Growth—+14.8+21.3+16.5—
Net Income Growth—+12.9+14.1+5.0—
EPS Growth—+13.0+14.3+4.8—
Total Assets Growth—+5.8+7.8+18.1—
Total Equity Growth—+13.1+8.0+15.7—
Cash from Operations Growth—+144.7+16.0-11.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 199%.